Press Release – For immediate release

BIOLIDICS CONTINUES TO GROW WITH IMPROVED FINANCIAL PERFORMANCE ACHIEVED IN HY2019; REVENUE IN HY2019 SURGES 59.0% WITH INCREASED PRODUCT SALES

- **Revenue in HY2019 increased by 59.0% to approximately S$1.00 million as compared to S$0.63 million in HY2018, driven mainly by increased sales of its ClearCell® FX1 system and CTChip® FR1 biochip**
- **A total of 5 partnerships for the development and commercialisation of clinical tests or laboratory-developed tests ("LDTs") in the field of circulating tumour cells using Biolidics' technology**
- **Once these LDTs and/or laboratory assays are approved clinically, it is expected to lead to an increase in the demand for ClearCell® FX1 system and higher usage of CTChip® FR1 biochips which are required to perform the liquid biopsy tests**

Singapore 7 August 2019 – **Biolidics Limited ("Biolidics" or the "Company"),** a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce today its first half financial results ("HY2019") for the financial year ending 31 December 2019.

With increased sales of its ClearCell® FX1 system and CTChip® FR1 biochip in HY2019, Biolidics' revenue surged 59.0% to S$1.00 million, as compared to S$0.63 million in HY2018. It is worth noting that Biolidics registered a revenue of S$1.27 million in FY2018.

Sales of ClearCell® FX1 system increased 29.1% to S$0.53 million in HY2019 as Japan-based Sysmex Corporation ("Sysmex"), one of the leading suppliers of hematology instruments, purchased more ClearCell® FX1 systems in relation to an assay development collaboration with Biolidics for LDTs.

Currently, Biolidics has entered into 5 partnerships, 4 in China and 1 with Sysmex, for the development and commercialisation of LDTs using Biolidics' ClearCell® FX1 system and CTChip® FR1 biochip.

Once these LDTs and/or laboratory assays are approved clinically, it is expected to lead to an increase in the demand for ClearCell® FX1 system and higher usage of CTChip® FR1 biochips which are required to perform the liquid biopsy tests.

Commenting on Biolidics' HY2019 results, Mr. Ivan Lew (廖光品), Executive Director and CEO of Biolidics, said: *"The increased prevalence of cancer is driving the growth of the global market for cancer diagnostics market and our first half revenue performance highlights the growing adoption of non-invasive liquid biopsy techniques and the continued execution of our go-to-market strategies.*

Reflecting the strong value propositions of our upstream technology, there is significant potential for further growth and sustainable development of our business within the cancer diagnostic market.

With a healthy balance sheet, we are confident in our ability to harness more opportunities that create more meaningful impact for cancer patients and shareholders."

- END -

This document is to be read in conjunction with Biolidics' exchange filings on 7 August 2019, which can be downloaded via www.sgx.com.

About Biolidics Limited
(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 system, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 system, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:

Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.